On February 1, 2012, Russian President Dmitry Medvedev signed into law Russia’s accession to the OECD’s Anti-Bribery Convention. The law was passed by Russia’s Duma, the lower house of the legislature, on January 13, 2012, and was ratified by the Federation Council, the upper house of the legislature, on January 25, 2012. In evaluating Russia’s bid to join the Convention, the OECD’s working group noted that the Russian law entitled “Federal Law dated May 4, 2011 No. 97-FZ On inclusion of changes to the Criminal Code of Russian Federation and to the Code of Administrative Offences in Connection with the Improvement of Government Administration in the Area of Fighting Corruption,” which President Medvedev signed on May 4, 2011, satisfies the requirements of the Convention. Russian Law No. 97-FZ changed the then existing anti-bribery provisions in the Criminal and Administrative Codes of Russia by significantly increasing monetary fines for bribery and was made applicable to both commercial bribery as well as bribery of foreign government officials. Because Law No. 97-FZ prohibits commercial bribery and both receiving and offering corrupt payments to foreign government officials, the law resembles the UK Bribery Act and can be said to have even further reach than the FCPA.
Related Insights
12 March 2025
Health Care Law Today
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA’s Declaration that Tirzepatide Shortage is Resolved; Plaintiff OFA Appeals
On March 5, 2025, one U.S. District Court ruled unequivocally in the Food & Drug Administration’s (FDA) favor in the case, Outsourcing Facilities Ass’n, et. al. v. U.S. Food and Drug Admin., et. al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15 (N.D. Tex. Mar. 5, 2025), denying plaintiffs’ motion for (1) a preliminary injunction (PI) prohibiting the FDA from taking action against Outsourcing Facilities Association (OFA) members and FarmaKeio based on their compounding of the drug ingredient tirzepatide pending final judgment in the case and (2) a stay pending conclusion of the review proceedings in response to the FDA’s declaration that the shortage of the diabetes and weight-loss tirzepatide products has been resolved.
12 March 2025
Health Care Law Today
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management (e.g., Wegovy®) and are now being explored for treating a wide range of health conditions.
11 March 2025
Consumer Class Defense Counsel
No Harm, No Foul: Greenwashing Lawsuit Dismissed for Lack of Article III Standing
It is well-settled that under Article III of the Constitution, United States federal courts are limited to trying “cases and controversies.”